Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Research Article

Neutrophil-lymphocyte, Lymphocyte-monocyte, and Platelet-lymphocyte Ratios: Non-invasive Biomarkers for Assessing Inflammatory Bowel Disease Activity

Author(s): Dhruvkumar M. Patel, Dhara K. Patel, Maitri M. Patel, Lalitkumar B. Patel, Ronak T. Shaikh, Neha T. Shaikh and Mukundkumar V. Patel*

Volume 19, Issue 3, 2025

Published on: 04 December, 2024

Page: [406 - 412] Pages: 7

DOI: 10.2174/0127722708330712241106074203

Price: $65

Abstract

Background: Inflammatory bowel diseases (IBD) necessitate cost-effective biomarkers for efficient management. This study aimed to explore the potential correlations of neutrophil-to-- lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) with IBD disease activity. Additionally, we assessed their associations with other inflammatory markers.

Methods: We recruited 180 IBD patients with over 12 months of disease duration, categorized into two groups: Group 1 (active IBD) with 113 cases and Group 2 (inactive IBD) with 67 cases, alongside 200 group-matched healthy controls (Group 3). Hemogram, NLR, LMR, PLR, hs-CRP, ESR, fecal calprotectin (FC), and relevant parameters were recorded.

Results: NLR and PLR were elevated, while LMR was decreased in active IBD patients compared to those in remission. The cutoff values for active IBD were determined as NLR > 1.98, LMR < 3.01, and PLR > 147, exhibiting sensitivity of 92%, 88%, and 91%, and specificity of 93%, 87%, and 89% respectively. Optimal cutoff values for IBD disease activity were CRP > 9.71, ESR > 24, and FC > 176. Multivariate logistic regression identified NLR, LMR, and PLR as robust parameters for discriminating IBD disease activity after adjusting for WBC, CRP, ESR, and FC markers (p < 0.05). NLR and PLR exhibited proportional increases with IBD severity, while LMR lacked such predictive capability.

Conclusion: NLR, PLR, and LMR emerge as simple, non-invasive, and cost-effective independent markers of IBD disease activity, complementing traditional markers like CRP and ESR.

Keywords: Neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, inflammatory markers, inflammatory bowel disease, Crohn's disease, ulcerative colitis.

Graphical Abstract
[1]
Feng W, Liu Y, Zhu L, Xu L, Shen H. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: A retrospective study. BMC Gastroenterol 2022; 22(1): 485.
[http://dx.doi.org/10.1186/s12876-022-02571-9] [PMID: 36424535]
[2]
Langley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory bowel disease and Neutrophil–Lymphocyte ratio: A systematic scoping review. J Clin Med 2021; 10(18): 4219.
[http://dx.doi.org/10.3390/jcm10184219] [PMID: 34575330]
[3]
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroenterol 2019; 114(3): 384-413.
[http://dx.doi.org/10.14309/ajg.0000000000000152] [PMID: 30840605]
[4]
Günay E, Sarınç Ulaşlı S, Akar O, et al. Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: A retrospective study. Inflammation 2014; 37(2): 374-80.
[http://dx.doi.org/10.1007/s10753-013-9749-1] [PMID: 24078279]
[5]
Targońska-Stępniak B, Zwolak R, Piotrowski M, et al. The relationship between hematological markers of systemic inflammation (Neutrophil-To-Lymphocyte, platelet-To-Lymphocyte, Lymphocyte-To-Monocyte Ratios) and ultrasound disease activity parameters in patients with rheumatoid arthritis. J Clin Med 2020; 9(9): 2760.
[6]
e W, Wang Z, Pang M, Lu Y, Fan H. The correlation between platelet-to-lymphocyte ratio and Neutrophil-to-Lymphocyte ratio with Hepatic Echinococcosis. J Inflamm Res 2021; 14(14): 2403-9.
[http://dx.doi.org/10.2147/JIR.S304307] [PMID: 34113147]
[7]
Qin B, Ma N, Tang Q, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol 2016; 26(3): 372-6.
[http://dx.doi.org/10.3109/14397595.2015.1091136] [PMID: 26403379]
[8]
Khan R, Quaiser S. Correlation of neutrophil–lymphocyte ratio with disease activity in rheumatoid arthritis. J Clin Sci 2020; 17(2): 46-8.
[http://dx.doi.org/10.4103/jcls.jcls_16_18]
[9]
Yao C, Liu X, Tang Z. Prognostic role of neutrophil–lymphocyte ratio and platelet–lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 2285-90.
[http://dx.doi.org/10.2147/COPD.S141760] [PMID: 28814856]
[10]
Pan L, Du J, Li T, Liao H. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio associated with disease activity in patients with Takayasu's arteritis: A case-control study. BMJ Open 2017; 7(4): e014451.
[http://dx.doi.org/10.1136/bmjopen-2016-014451]
[11]
Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111: 176-81.
[http://dx.doi.org/10.1016/j.lungcan.2017.07.024] [PMID: 28838390]
[12]
Weng W, Chen X, Gong S, Guo L, Zhang X. Preoperative neutrophil–lymphocyte ratio correlated with glioma grading and glioblastoma survival. Neurol Res 2018; 40(11): 917-22.
[http://dx.doi.org/10.1080/01616412.2018.1497271] [PMID: 30074469]
[13]
Stephanie L, Gold BL, Gordon Y, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR): Novel predictors of disease activity in patients with inflammatory bowel disease. Gastroenterol 2020; 158(6): S-703.
[http://dx.doi.org/10.1016/S0016-5085(20)32448-3]
[14]
Argeny S, Stift A, Bergmann M, et al. Prognostic value of preoperative neutrophil-to-lymphocyte ratio in Crohn’s disease. Wien Klin Wochenschr 2018; 130(11-12): 398-403.
[http://dx.doi.org/10.1007/s00508-018-1322-3] [PMID: 29435759]
[15]
Celikbilek M, Dogan S, Ozbakır O, et al. Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal 2013; 27(1): 72-6.
[http://dx.doi.org/10.1002/jcla.21564] [PMID: 23292894]
[16]
Akpinar MY, Ozin YO, Kaplan M, et al. Platelet-to-lymphocyte ratio and Neutrophil-to-lymphocyte ratio predict mucosal disease severity in ulcerative colitis. J Med Biochem 2018; 37(2): 155-62.
[17]
Xu M, Cen M, Chen X, et al. Correlation between serological biomarkers and disease activity in patients with inflammatory bowel disease. Biomed Res Int 2019; 2019: 6517549.
[http://dx.doi.org/10.1155/2019/6517549]
[18]
Yamamoto-Furusho JK, Mendieta-Escalante EA. Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. PLoS One 2020; 15(4): e0231988.
[http://dx.doi.org/10.1371/journal.pone.0231988] [PMID: 32315368]
[19]
Torun S, Tunc BD, Suvak B, et al. Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: A promising marker in predicting disease severity. Clin Res Hepatol Gastroenterol 2012; 36(5): 491-7.
[http://dx.doi.org/10.1016/j.clinre.2012.06.004] [PMID: 22841412]
[20]
Acarturk G, Acay A, Demir K, Ulu MS, Ahsen A, Yuksel S. Neutrophil-to-lymphocyte ratio in inflammatory bowel disease – As a new predictor of disease severity. Bratisl Med J 2015; 116(4): 213-7.
[http://dx.doi.org/10.4149/BLL_2015_041] [PMID: 25773946]
[21]
Jeong Y, Jeon SR, Kim HG, et al. The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis. Intest Res 2021; 19(1): 62-70.
[http://dx.doi.org/10.5217/ir.2019.09156] [PMID: 32375208]
[22]
Fidan K, Kocak MZ. Assessment of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ulcerative colitis: A retrospective study. Eurasian J Med Oncol 2017; 1(4): 224-7.
[23]
Demir AK, Demirtas A, Kaya SU, et al. The relationship between the neutrophil–lymphocyte ratio and disease activity in patients with ulcerative colitis. Kaohsiung J Med Sci 2015; 31(11): 585-90.
[http://dx.doi.org/10.1016/j.kjms.2015.10.001] [PMID: 26678939]
[24]
Okba AM, Amin MM, Abdelmoaty AS, et al. Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity. Auto Immun Highlights 2019; 10(1): 4.
[http://dx.doi.org/10.1186/s13317-019-0114-8] [PMID: 32257060]
[25]
Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13(3): 159-75.
[http://dx.doi.org/10.1038/nri3399] [PMID: 23435331]
[26]
Rodríguez-Perlvárez ML, García-Sánchez V, Villar-Pastor CM, et al. Role of serum cytokine profile in ulcerative colitis assessment. Inflamm Bowel Dis 2012; 18(10): 1864-71.
[http://dx.doi.org/10.1002/ibd.22865] [PMID: 22238172]
[27]
Zhou GX, Liu ZJ. Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease. J Dig Dis 2017; 18(9): 495-503.
[http://dx.doi.org/10.1111/1751-2980.12540] [PMID: 28857501]
[28]
Naito Y, Takagi T, Yoshikawa T. Neutrophil-dependent oxidative stress in ulcerative colitis. J Clin Biochem Nutr 2007; 41(1): 18-26.
[http://dx.doi.org/10.3164/jcbn.2007003] [PMID: 18392100]
[29]
Chen YH, Wang L, Feng SY, Cai WM, Chen XF, Huang ZM. The relationship between C-Reactive protein/Albumin ratio and disease activity in patients with inflammatory bowel disease. Gastroenterol Res Pract 2020; 2020: 1-8.
[http://dx.doi.org/10.1155/2020/3467419] [PMID: 32655630]
[30]
Furukawa S, Yagi S, Shiraishi K, et al. Association between platelet count and mucosal healing in Japanese patients with ulcerative colitis: A cross-sectional study. BMC Gastroenterol 2020; 20(1): 384.
[http://dx.doi.org/10.1186/s12876-020-01538-y]
[31]
Öztürk ZA, Dag MS, Kuyumcu ME. Could platelet indices be new biomarkers for inflammatory bowel diseases? Eur Rev Med Pharmacol Sci 2013; 17(3): 334-41.
[32]
Nakarai A, Kato J, Hiraoka S, et al. An elevated platelet count increases the risk of relapse in Ulcerative Colitis patients with Mucosal healing. Gut Liver 2018; 12(4): 420-5.
[http://dx.doi.org/10.5009/gnl17236]
[33]
Lee SH, Kim MJ, Chang K, et al. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol 2017; 17(1): 110.
[http://dx.doi.org/10.1186/s12876-017-0669-7] [PMID: 29061121]
[34]
Takashima S, Kato J, Hiraoka S, et al. Evaluation of Mucosal healing in ulcerative colitis by Fecal Calprotectin vs. Fecal immunochemical test. Am J Gastroenterol 2015; 110(6): 873-80.
[http://dx.doi.org/10.1038/ajg.2015.66] [PMID: 25823769]
[35]
Cherfane CE, Gessel L, Cirillo D, Zimmerman MB, Polyak S. Monocytosis and a low lymphocyte to monocyte ratio are effective biomarkers of Ulcerative Colitis disease activity. Inflamm Bowel Dis 2015; 21(8): 1769-75.
[http://dx.doi.org/10.1097/MIB.0000000000000427] [PMID: 25993688]

Rights & Permissions Print Cite
© 2026 Bentham Science Publishers | Privacy Policy